Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Trial Profile

Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2018

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Rivoceranib (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jan 2018 Status changed from not yet recruiting to active, no longer recruiting, as reported in an abstract presented at the 2018 Gastrointestinal Cancers Symposium
    • 20 Jan 2018 Results (n=30) presented at the 2018 Gastrointestinal Cancers Symposium
    • 21 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top